Bicara Therapeutics (NASDAQ:BCAX) Trading Down 7% - Here's Why

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price dropped 7% during mid-day trading on Tuesday . The company traded as low as $14.15 and last traded at $14.29. Approximately 222,907 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 373,259 shares. The stock had previously closed at $15.36.

Analysts Set New Price Targets

BCAX has been the topic of a number of research analyst reports. HC Wainwright raised their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Wedbush restated an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $41.20.

Bicara Therapeutics Trading Down 5.6 %

The company has a 50-day simple moving average of $13.49.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently modified their holdings of the business. RA Capital Management L.P. bought a new stake in Bicara Therapeutics during the third quarter worth about $177,169,000. Red Tree Management LLC acquired a new position in Bicara Therapeutics during the fourth quarter worth $55,230,000. FMR LLC bought a new stake in Bicara Therapeutics during the third quarter worth $57,913,000. Adage Capital Partners GP L.L.C. lifted its stake in Bicara Therapeutics by 171.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock valued at $37,893,000 after acquiring an additional 1,375,265 shares during the last quarter. Finally, Braidwell LP lifted its stake in Bicara Therapeutics by 20.7% in the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company's stock valued at $34,851,000 after purchasing an additional 343,059 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads